Patents Represented by Attorney, Agent or Law Firm Briana C. Buchholz
-
Patent number: 6800457Abstract: A specific locus (hot spot) for recombinant gene expression has been identified in the genome of Chinese hamster ovary cells. A DNA vector containing the hot spot causes high levels of recombinant gene expression following transfection and stable integration. The selection and cloning of the specific locus and the expression of recombinant genes is disclosed, as are the DNA vectors and the host cells.Type: GrantFiled: December 16, 2002Date of Patent: October 5, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Kanaka Raju Koduri, John T. Miller, Pallaiah Thammana
-
Patent number: 6677298Abstract: Obesity is a common clinical problem in most developed nations and is also rapidly becoming a major health concern in developing nations. Overweight individuals frequently suffer from several metabolic disorders such as insulin resistance, type 2 diabetes and dyslipidemia. This invention discloses proof of principle for the role PPAR&dgr; (also known as &bgr;) plays in the development of diet-induced obesity. In accordance with the present invention, a new method for treating obesity, insulin resistance and hyperlipidemia through administration of a pharmaceutical composition containing a chemical agent that antagonizes the function of PPAR&dgr;(&bgr;) protein, decreases PPAR&dgr;(&bgr;) gene expression and or transactivation of PPAR&dgr;(&bgr;) target gene expression is disclosed.Type: GrantFiled: July 19, 2001Date of Patent: January 13, 2004Assignee: Bristol-Myers Squibb CompanyInventor: Narayanan Hariharan
-
Patent number: 6528300Abstract: The invention provides a glutaryl 7-ACA amidase from Pseudomonas diminuta strain BS-203, which catalyzes the hydrolysis of 7-&bgr;-(4-carboxybutanamido)-cephalosporanic acid to 7-aminocephalosporanic acid and glutaric acid. The invention also provides nucleic acid sequences, vectors, and host cells useful in the production of this amidase. The glutaryl 7-ACA amidase can be used for the preparation of 7-aminocephalosporanic acid.Type: GrantFiled: September 21, 2001Date of Patent: March 4, 2003Assignee: Bristol-Myers Squibb Co.Inventors: Ross Binder, Joanne L. Brown, Thomas J. Franceschini, William V. Burnett, Michael Politino, Suo Win Liu, Sean M. Tonzi
-
Patent number: 6521419Abstract: A specific locus (hot spot) for recombinant gene expression has been identified in the genome of Chinese hamster ovary cells. A DNA vector containing the hot spot causes high levels of recombinant gene expression following transfection and stable integration. The selection and cloning of the specific locus and the expression of recombinant genes is disclosed, as are the DNA vectors and the host cells.Type: GrantFiled: August 31, 1999Date of Patent: February 18, 2003Inventors: Kanakaraju Koduri, John T. Miller, Pallaiah Thammana
-
Patent number: 6518011Abstract: The present invention is directed generally to methods and composition for monitoring the processing of epitope-tagged beta-APP. More specifically, the present invention relates to the use of such methods and composition for monitoring responses of cells expressing such epitope-tagged beta-APP or fragments thereof or cell free systems containing the epitope-tagged polypeptides to therapy of diseases associated with an altered metabolism of the beta amyloid precursor protein (APP), and for screening and evaluation of potential drugs for the treatment of these disorders, including Alzheimer's disease (AD).Type: GrantFiled: January 12, 2000Date of Patent: February 11, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Dietmar A. Seiffert, Thomas J. Mitchell
-
Patent number: 6403360Abstract: The present invention relates to KCNQ proteins defining potassium channels. In particular, the invention concerns the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 proteins reported herein. KCNQ2 and KCNQ3 proteins are nervous system-selective and may be involved in neurotransmission and neuroprotection. The KCNQ2 and KCNQ3 of the present invention can be used to assay for modulators of the proteins, which would be useful in treatment of such disorders as ataxia, myokymia, seizures, Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, epilepsy, stroke, and the like.Type: GrantFiled: June 26, 1998Date of Patent: June 11, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Michael A. Blanar, Paul C. Levesque, Wayne A. Little, Michael G. Neubauer, Wen-Pin Yang
-
Patent number: 6130348Abstract: The present invention relates to a new method for making compounds of formula ##STR1## and intermediates for making compounds of formual II. The compounds of this invention are useful intermediates for the manufacture of pharmacologically active compounds suitable for the treatment of viral infections, particularly, those caused by HIV and other retroviruses.Type: GrantFiled: March 19, 1998Date of Patent: October 10, 2000Assignee: Hoffmann-La Roche Inc.Inventor: Hans Hilpert
-
Patent number: 6080837Abstract: This invention relates to a novel process for the synthesis of vasoactive intestinal peptide analog Ac(1-31)--NH.sub.2 from four protected peptide fragments.Type: GrantFiled: February 7, 1997Date of Patent: June 27, 2000Assignee: Hoffmann-La Roche Inc.Inventors: David Robert Bolin, Waleed Danho, Arthur M. Felix
-
Patent number: 6046012Abstract: This disclosure relates to novel antibodies specific to the recently discovered receptor to human interleukin 12 (IL-12R). The antibodies to IL-12R, most preferably, the monoclonal antibodies to that protein, are useful in determining the status of the human immune system and as diagnostic reagents or potential therapeutic reagents for conditions involving imbalances in IL-12 levels or cell types sensitive to IL-12 activation.Further aspects of the disclosure relate to methods of producing and purifying such novel antibodies and hybridoma cell lines capable of their production. Another aspect of the disclosure relates to an immunoprecipitation assay for the detection of solubilized IL-12R which employs, in a preferred embodiment, monoclonal antibodies to the receptor of the present invention covalently bound to Protein G-Sepharose resin.Type: GrantFiled: January 27, 1997Date of Patent: April 4, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Richard Anthony Chizzonite, Theresa Patricia Truitt
-
Patent number: 6039975Abstract: A novel delivery system for targeting drugs to the colon is herein described. The system is a tablet comprised of three parts: 1) an outer enteric coating, 2) an inner semi-permeable polymer membrane containing a plasticizer and 3) a central core comprising swelling excipients and an active ingredient. The novel dosage form described herein will release the drug consistently in the colon by a time-dependent explosion mechanism.This delivery system is particularly suitable for delivering viral protease inhibitors to the colon.Type: GrantFiled: September 20, 1996Date of Patent: March 21, 2000Assignee: Hoffman-La Roche Inc.Inventors: Navnit Hargovindas Shah, Aruna M. Railkar, Wantanee Phuapradit
-
Patent number: 6030953Abstract: The present invention provides orally administrable pharmaceutical compositions containing an inhibitor of gastrointestinal lipase, and at least one compound selected from the group consisting of chitosan, its derivatives and salts thereof. Methods are provided for preventing and treating anal leakage of oil in a patient to whom a composition containing an inhibitor of gastrointestinal lipase is orally administered.Type: GrantFiled: August 10, 1999Date of Patent: February 29, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Jacques Bailly, Andre Fleury, Paul Hadvary, Hans Lengsfeld, Hans Steffen
-
Patent number: 6008342Abstract: The invention provides an immunogenic polypeptide having the amino acid sequenceM A K S M L S G I V F A G L V A A A A A - S S A N S A A N V S V L E S G P A V Q E - V P A R T V T A R L A K P L L L L S A L - A A T L A A A F L V L Q C F N I I S S N - N Q Q T S V R R L A A G G A C G D E E D - A D E G T S Q Q A S R R R R K P D T P A - A D K Y D F V G G T P V S V T E P N V D - E V L I Q I R N K Q I F L K N P W T G Q - E E Q V L V L E R Q S E E P I L I V A R - T R Q T L E G Y L G S Q A L A Q D G K T - A K E E K V E G G K T H R R Y K V K S S - D P G Y G F P Y T T V L D G V P V G T D - E D G Y V V E V L M K T G P H G G V D M - M T S T A S Q G K F C G V L M D D G K G - N L V D G Q G R K I T A V I G M L T Q P - D T E F R S G P G D D E D D E (SEQ ID NO:1)and fragments thereof,which polypeptides are capable of inducing an immune response against Eimeria parasites, and the DNA encoding such polypeptides, as well as recombinant vectors and recombinant viruses containing the said DNA or fragments thereof and transformed micrType: GrantFiled: December 19, 1996Date of Patent: December 28, 1999Assignee: Roche Vitamins Inc.Inventors: Mary-Helen Binger, Luis Pasamontes
-
Patent number: 5969139Abstract: The invention relates to new and known tricyclic dione derivatives of the general formula ##STR1## wherein W represents hydrogen or lower alkyl;X represents lower alkyl;Y represents NR1;R.sup.1 represents hydrogen, lower alkyl, lower alkoxycarbonyl or lower alkoxycarbonyl-lower alkyl;Z represents aryl or heteroaryl optionally substituted by one or more halo, cyano, nitro, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, COR.sup.2, OCOR.sup.2, CO.sub.2 R.sup.2, OR.sup.2, S(O).sub.n R.sup.2, NR.sup.2 R.sup.3, N(R.sup.4)COR.sup.5, Ar, Ar-lower alkyl, Het or Het-lower alkyl substituents and/or on adjacent carbon atoms by lower alkylenedioxy;R.sup.2, R.sup.3, R.sup.4 and R.sup.5 each individually represent hydrogen, lower alkyl, Ar, Ar-lower alkyl, Het or Het-lower alkyl substituents; or R.sup.2 and R.sup.3 together represent the group --CH.dbd.CH--CH.dbd.CH-- or --CH.dbd.N--CH.dbd.Type: GrantFiled: August 6, 1997Date of Patent: October 19, 1999Assignee: Hoffmann-La Roche Inc.Inventors: Joseph Armstrong Martin, Bradley Stuart Sherborne, Gareth Mark Taylor
-
Patent number: 5928636Abstract: The present invention provides a combination of IL-12 and IFN.alpha. together with a pharmaceutically acceptable carrier useful for treatment and prophylaxis of infectious diseases, preferably chronic infectious diseases and more preferably viral infections, e.g. HSV, HIV, Hepatitis B, Hepatitis C, papilloma etc., bacterial infections, e.g. tuberculosis, salmonellosis, listeriosis, etc., and parasite infections, e.g. malaria, leishmaniasis, and schistosomiasis. These compositions are characterized by the synergistic interaction of IL-12 and IFN.alpha.. The present invention also provides the use of the above combination for the treatment and prophylaxis of infectious diseases.Type: GrantFiled: April 30, 1997Date of Patent: July 27, 1999Assignee: Hoffmann-La Roche Inc.Inventors: Gottfried Alber, Jacqueline Anne Carr, Frank Albert Mattner, Michael John Mulqueen, Kathrin Palmer, Jane Andre Louise Rogerson
-
Patent number: 5914404Abstract: The present invention is concerned with a novel process for the manufacture of quinargine ##STR1## (N-(2-quinolylcarbonyl)-asparagine) based on the reaction of the succinimide ester ##STR2## with asparagine or asparagine salts in an aqueous reaction medium at a neutral pH value.Type: GrantFiled: July 18, 1997Date of Patent: June 22, 1999Assignee: Hoffmann-La Roche Inc.Inventor: Wolfgang Gohring
-
Patent number: 5849860Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.Type: GrantFiled: June 1, 1995Date of Patent: December 15, 1998Assignee: Hoffmann-La Roche Inc.Inventors: John Hakimi, Patricia Kilian, Perry Rosen
-
Patent number: 5837807Abstract: This invention is directed to tetrahydronaphthalene compounds of the formula ##STR1## wherein R.sup.1 is hydrogen, bromine, cyano, formyl, hydroxy, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, aryloxy, lower aralkoxy or aryl; R.sup.2 is an amino acid residue or a chain of 2 to 20 amino acid residues wherein reactive moieties in the side chains of the amino acid residue(s) is/are protected or unprotected, and wherein the amino group of the N-terminal amino acid is a free or protected amino group; A.sup.1, A.sup.2, A.sup.3 and A.sup.4 each are .alpha.-amino acid residues wherein A.sup.1 and A.sup.2 are in the L configuration and A.sup.3 and A.sup.4 are in the D configuration when the .alpha.-C atom of said .alpha.-amino acid residue is asymmetric; X is oxygen or sulphur; Y is a residue of the formula ##STR2## n is 0 or 1; R.sup.3 is hydrogen or lower alkyl; R.sup.Type: GrantFiled: February 27, 1996Date of Patent: November 17, 1998Assignee: Hoffmann-La Roche Inc.Inventors: Christine Abrecht, Alfred Grieder, Klaus Muller, Daniel Obrecht
-
Patent number: 5831022Abstract: A process for the production of essentially homogeneous soluble, stable, endotoxin free human recombinant interleukin-1.alpha. of enhanced specific activity is described. The process involves breaking transformed microbial cells containing expressed human interleukin-1.alpha. and separating the soluble supernatant from the insoluble cell components and then passing the supernatant through gel chromatography and ion-exchange chromatography steps.Type: GrantFiled: February 18, 1986Date of Patent: November 3, 1998Assignee: Hoffmann-La Roche Inc.Inventor: Alvin Seth Stern
-
Patent number: 5780597Abstract: The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.Type: GrantFiled: June 2, 1995Date of Patent: July 14, 1998Assignee: Hoffmann-La Roche Inc.Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan
-
Patent number: 5759827Abstract: Compounds of the formulaR.sup.1 --NH--A Iwherein R.sup.1 is an acyl moiety of a C.sub.12-40 aliphatic carboxylic acid, A is the residue of a oligopeptide devoid of one amino group, and --NH--A contains at least one positively charged amino acid, or derivatives thereof can be used for transferring anionic macromolecules into cells.Type: GrantFiled: November 20, 1996Date of Patent: June 2, 1998Assignee: Hoffmann-La Roche Inc.Inventors: Jean-Yves Legendre, Andreas Supersaxo, Arnold Trzeciak